Ja Min Byun1, Junshik Hong2, Sung-Soo Yoon1, Youngil Koh1, Chan-Young Ock1, Tae Min Kim1, Ji Hyun Lee3, Sung-Hyun Kim3, Jeong-Ok Lee4, Soo-Mee Bang4, Ho-Young Yhim5, Sung Hwa Bae6, Yeung-Chul Mun7, Doyeun Oh8. 1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address: alertjun@hanmail.net. 3. Department of Internal Medicine, Dong-A University of College of Medicine, Busan, Republic of Korea. 4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 5. Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Republic of Korea. 6. Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Republic of Korea. 7. Department of Internal Medicine, Ewha Women's University School of Medicine, Seoul, Republic of Korea. 8. Department of Internal Medicine, School of Medicine, CHA University, Seongnam, Republic of Korea.
Abstract
BACKGROUND: Venous thromboembolism (VTE) may lead to diminished quality of life and ultimately worse prognosis in cancer patients, but there is limited data on the incidence, risk factors and mortality impact of VTE in Asian primary central nervous system lymphoma (PCNSL) patients. OBJECTIVES: To report the incidence, risk factors and mortality impact of VTE in Asian PCNSL patients. METHODS: From 7 academic centers in Korea, 235 newly diagnosed PCNSL patients undergoing chemotherapy were retrospectively identified during period of January 2004 to September 2018. RESULTS: All patients but 12 (6 T-cell, 6 other B-cell) had diffuse large B-cell lymphoma. During the median follow-up of 21 months, 33 patient (14.0%) developed VTE. Of the VTE events, 11 (33.3%) were deep vein thrombosis (DVT), 15 (45.5%) were pulmonary thromboembolism (PTE), and 7 (21.2%) were DVT with PTE. The median time to VTE was 2 months and the one-year actuarial incidence was 11.7%. On multivariate analysis, ECOG performance ≥2, age >60 years, female sex, and Hb <10 g/dL were independently associated with VTE. The patients with VTE were associated with shorter disease specific survival (P = 0.046) and overall survival (P = 0.022). CONCLUSION: Overall, the incidence of VTE in Asian PCNSL seems to be lower compared to Western population. As VTE development is associated with overall survival and indicative of relapse, careful close monitoring is warranted.
BACKGROUND:Venous thromboembolism (VTE) may lead to diminished quality of life and ultimately worse prognosis in cancerpatients, but there is limited data on the incidence, risk factors and mortality impact of VTE in Asian primary central nervous system lymphoma (PCNSL) patients. OBJECTIVES: To report the incidence, risk factors and mortality impact of VTE in Asian PCNSLpatients. METHODS: From 7 academic centers in Korea, 235 newly diagnosed PCNSLpatients undergoing chemotherapy were retrospectively identified during period of January 2004 to September 2018. RESULTS: All patients but 12 (6 T-cell, 6 other B-cell) had diffuse large B-cell lymphoma. During the median follow-up of 21 months, 33 patient (14.0%) developed VTE. Of the VTE events, 11 (33.3%) were deep vein thrombosis (DVT), 15 (45.5%) were pulmonary thromboembolism (PTE), and 7 (21.2%) were DVT with PTE. The median time to VTE was 2 months and the one-year actuarial incidence was 11.7%. On multivariate analysis, ECOG performance ≥2, age >60 years, female sex, and Hb <10 g/dL were independently associated with VTE. The patients with VTE were associated with shorter disease specific survival (P = 0.046) and overall survival (P = 0.022). CONCLUSION: Overall, the incidence of VTE in Asian PCNSL seems to be lower compared to Western population. As VTE development is associated with overall survival and indicative of relapse, careful close monitoring is warranted.